Cancer Medicines Outcomes Programme PHS (CMOP-PHS) report - NCMAG
SACT treatment of adults with soft tissue sarcoma following prior chemotherapy: NCMAG128

About this release

This release by Public Health Scotland (PHS) uses information from the National SACT dataset.

This work was requested by the National Cancer Medicines Advisory Group (NCMAG) to support their decision-making processes. NCMAG are assessing the use of pazopanib for the treatment of adult patients with selective subtypes of soft tissue sarcoma (STS) who have either received prior chemotherapy for metastatic disease, or who have progressed within twelve months of adjuvant or neoadjuvant (from here on described as "(neo) adjuvant") therapy (NCMAG128).

The aim of this work was to capture real-world evidence (RWE) from Scotland on the use of systemic anti-cancer therapy (SACT) for adults with selective subtypes of STS who have either received prior chemotherapy for metastatic disease, or who have progressed within twelve months of (neo) adjuvant therapy. Details of the presumptions made to identify this cohort are described in Section 2.3.1. of the main report. This work will enable the NCMAG members to assess the relevance of information, provided as part of the assessment process, to patients in Scotland.

The objectives were to:

• Determine the number of patients prescribed SACT for the treatment of selective subtypes of STS who have either received prior SACT for metastatic disease, or who have progressed within twelve months of (neo) adjuvant therapy.
• Describe SACT usage for the treatment of patients with selective subtypes of STS who have either received prior SACT for metastatic disease, or who have progressed within twelve months of (neo) adjuvant therapy.
• Describe the baseline characteristics of patients who have received SACT for the treatment of selective subtypes of STS, who have either received prior SACT for metastatic disease or who have progressed within twelve months of (neo) adjuvant therapy.
• Describe the duration of treatment of selective subtypes of STS for patients who have either received prior SACT for metastatic disease, or who have progressed within twelve months of (neo) adjuvant therapy.